Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jun 13, 2021 in Melanoma | 0 comments

In a nutshell

This study investigated the effectiveness of dabrafenib (Tafinlar) plus trametinib (Mekinist) treatment before surgery for patients with unresectable advanced-stage melanoma. The data showed that this treatment was effective before surgery and allowed for the removal of tumors.

Some background

Melanoma is an aggressive type of skin cancer. It has a high tendency to spread to other parts of the body (metastasis). In stage 3 or 4 melanoma, cancer has spread to nearby lymph nodes. The main form of treatment is the surgical removal of tumors. Tumors that cannot be removed surgically (unresectable) can be difficult to treat. Patients with unresectable tumors often have a poorer prognosis.

BRAF and MEK are the most common mutated (abnormal) genes in melanoma. These mutations allow tumors to grow at a rapid rate. Using drugs that target these mutations can improve survival. Dabrafenib is a drug that targets BRAF-mutant cancer cells. Trametinib is a drug that inhibits MEK. It has been shown that dabrafenib combined with trametinib before surgery (neoadjuvant) was safe and effective for patients with resectable stage 3 melanoma. However, there are very few studies investigating the effectiveness of dabrafenib plus trametinib treatment before surgery for patients with unresectable advanced-stage melanoma.

Methods & findings

This study involved 21 patients with unresectable metastatic stage IIIC/IV melanoma. All patients were treated with dabrafenib and trametinib for 8 weeks. All patients underwent then a PET/CT scan to scan for sufficient reduction of the tumor. If this was achieved, the patients were treated by surgical removal of the tumor (resection). The average follow-up time was 50 months.

85.7% (18) of the patients achieved sufficient reduction of the tumor and underwent surgery. 17 of these patients had complete removal of the tumor. The average survival without cancer coming back was 9.9 months in patients undergoing surgery. The average survival without cancer worsening was 12.4 months. The overall survival rate at 1-year was 100% and at 2-years was 85%.

The most common side effects after dabrafenib/trametinib treatment were fever, chills, fatigue, nausea, and muscle pain.

The bottom line

This study concluded that treatment with dabrafenib and trametinib before surgery for patients with unresectable advanced stage melanoma was effective to allow for resection of the tumor.

The fine print

The sample size was very small. During this study, dabrafenib and trametinib treatment after surgery became the new standard of care in patients with resectable stage III melanoma.

Published By :

Annals of Surgery

Date :

Apr 09, 2021

Original Title :

Neoadjuvant Cytoreductive Treatment with BRAF/MEK Inhibition of prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single Arm, Open-label Phase II Trial.

click here to get personalized updates